Related Experiment Video
Updated: May 7, 2026
10:58
Protein WISDOM: A Workbench for In silico De novo Design of BioMolecules
Published on: July 25, 2013
Template-constrained cyclic sulfopeptide HIV-1 entry inhibitors
Jonathan G Rudick1, Meg M Laakso, Ashley C Schloss
1Department of Biochemistry and Biophysics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA. jon.rudick@stonybrook.edu.
Organic & Biomolecular Chemistry
|September 26, 2013
Summary
Researchers designed novel cyclic sulfopeptides to block HIV-1 entry by mimicking a monoclonal antibody loop. Three potent sulfopeptides were synthesized, showing promise in complementing existing HIV-1 therapies.
Area of Science:
- Medicinal Chemistry
- Virology
- Immunology
Background:
- HIV-1 entry is a critical target for antiviral therapies.
- Monoclonal antibodies (mAbs) can neutralize viral entry.
- CCR5 antagonists are established HIV-1 entry inhibitors.
Purpose of the Study:
- To rationally design and synthesize novel cyclic sulfopeptides that inhibit HIV-1 entry.
- To explore the potential of template-constrained peptides in antiviral drug discovery.
- To identify sulfopeptides that complement the activity of CCR5 antagonists.
Main Methods:
- Design of cyclic sulfopeptides based on a monoclonal antibody (mAb) 412d loop.
- Synthesis of sulfopeptides using Fmoc-Tyr(SO3DCV)-OH.
- Evaluation of HIV-1 entry inhibition and synergy with CCR5 antagonists.
Main Results:
- Successful rational design of template-constrained cyclic sulfopeptides.
- Synthesis of a focused library of sulfopeptides.
- Identification of three cyclic sulfopeptides that inhibit HIV-1 entry.
- Demonstration that identified sulfopeptides complement CCR5 antagonist activity.
Conclusions:
- Cyclic sulfopeptides can be rationally designed to inhibit HIV-1 entry.
- The identified sulfopeptides represent a promising new class of HIV-1 entry inhibitors.
- These findings offer a novel strategy for developing combination therapies against HIV-1.
